Neurocrine Biosciences, Inc. has announced a second long term Phase III trial with highly positive efficacy results from its three month pivotal study, referred to as "SLEEP," the Study of Long-term
Bavarian Nordic has announced that it has received the requirements from the U.S. government's Department of Health and Services (HHS), for the purchase of 20 million doses of an MVA-based sma
India's Ranbaxy Laboratories, seven anti- AIDS drugs, have been added to World Health Organisation's (WHO) prequalification list for use in poor countri
Solution BioSciences, Inc., has announced a new antimicrobial system, called Bromitize, to reduce salmonella and other carcass bacteria during poultry processing. The antimicrobial activity is based on a patented bromine chemical technology. Th
Drug company GlaxoSmithKline (GSK) is disputing claims that its antidepressant Paxil was linked to an increased suicide risk in adults.The study, published this week, by scientists in Norway, suggests the antidepressant was linked to an increas
Because of the very high costs in developing drugs for rare genetic diseases, and the low return on investment, the pharmaceutical industry has rarely developed specific treatments for many of these diseases. But a new public-private partnership, calle
Solvay Pharmaceuticals and CV Therapeutics have announced that the U.S. Food and Drug Administ
EntreMed a clinical-stage pharmaceutical company developing therapeutics primarily for the treatment of cancer and inflammatory diseases, has announced the presentation of positive preclinical result
The Pharmacy Care Alliance today announced that it received approval from Medicare to begin education, outreach and enrollment activities for its Medicare-approved drug discount card on May 3. The Centers for Medicare an
The transaction is subject to normal conditions and is expected to close in the fourth quarter.
Meridica is a drug delivery technology company that designs and develops technologies for the pharmaceutical industry. It was established by PA Consulting Group, the management, systems and technology consulting firm, in May 2001 as part of the firm's venture program. In October 2003, Pfizer purchased a 10% interest in the company and licensed the rights to Meridica's dry powder inhaler.
Kelvin Cooper, Ph.D., Pfizer Senior Vice President, Worldwide Pharmaceutical Sciences, said: "The acquisition of Meridica strengthens Pfizer's presence in the growing allergy and respiratory therapeutic area, where there remains a high level of unmet medical need. Meridica has a proven-track record in developing technologically advanced drug delivery systems and its strength in this area will help Pfizer accelerate the development of allergy and respiratory product candidates in our pipeline."
Meridica's Chief Executive Officer, Dr Ian J Smith, said: "We are delighted to be joining such a successful, world-class pharmaceutical company. It is a tremendous endorsement of both Meridica's technologies and our committed and innovative staff. We are very excited about the future and our work in developing new products that will benefit millions of patients with respiratory disease."
Jon Moynihan, Executive Chairman of PA, said: "This deal with Pfizer is recognition of Meridica's major achievements, accomplished in a startlingly swift timeframe; its innovative technologies; and PA's wider venture program. The deal offers a healthy return to our shareholders, giving PA additional confidence to invest further in some of the promising new ventures that we have coming through at the moment. The future holds significant opportunity for Meridica and we wish our colleagues every success with Pfizer."
http://www.pfizer.com